NovaBay Pharmaceuticals (NBY) CEO pay: $366,461 actually paid in FY2024
$NBY · NovaBay Pharmaceuticals, Inc.Data through FY2024 — latest proxy filed 2026-02-10, checked for new filings 2026-08-21. Every number links to its source.
0.1× the tracked-company median CEO pay ($3.9M).
Pay vs. Performance (Compensation Actually Paid)
What the CEO was actually paid, by fiscal year
What $100 invested was worth, company vs peer group
Pay-vs-Performance table
| FY | CEO pay on paper | CEO pay actually earned | Other top execs (avg) | Value of $100 invested since FY2021 | Same, peer group since FY2021 | Net income |
|---|---|---|---|---|---|---|
| 2024 | $365,177 | $366,461 | $220,295 | $0.13 | — | -$7.2M |
| 2023 | $364,146 | $358,857 | $189,734 | $0.84 | — | -$9.6M |
| 2022 | $364,954 | $111,489 | $108,806 | $7.99 | — | -$10.6M |
| 2021 | $795,521 | $490,901 | $422,207 | $54.03 | — | -$5.8M |
Frequently asked
How much did the NBY CEO make in 2024?
$366,461 in Compensation Actually Paid (CAP) as NovaBay Pharmaceuticals, Inc.'s CEO (the filing reports this year's PEO pay without tagging which named executive it belongs to), updated 2026-02-10.
What is pay vs. performance (PvP)?
An SEC disclosure (Item 402(v), required since FY2022) linking named-executive pay to company total shareholder return (TSR) over up to 5 years.
What is Compensation Actually Paid (CAP)?
CAP starts from the Summary Compensation Table total and adjusts equity awards to fair value as of each year-end/vesting date, rather than grant-date value — see the glossary entry for the full walk-through.
Also on NBY: SEC & DOJ enforcement actions · CEO track-record ranking · Glossary